To test the combined effect of these inhibitors on cell signaling pathways in ovarian cancer cells, we treated SKOV3 cells with sunitinib and dasatinib, alone or in combination, for 24 h, then measured the expression of the phosphorylated and total forms of STAT3, SRC, AKT, and MAPK by Western blot (Figure 1B and Figure S1). The gene discussed is STAT3; the disease is ovarian carcinoma.